Clinical Trial Update: Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Nivolumab for patients with refractory or relapsed multiple myeloma; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED